Lingchen Li
Overview
Explore the profile of Lingchen Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng L, Lin F, Cai D, Zhang L, Yin C, Qi Y, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):128.
PMID: 40024929
Background And Objectives: Immune checkpoint inhibitors (ICIs) bring cancer patients tumor control and survival benefits, yet they also trigger immune-related adverse effects (irAEs), notably checkpoint inhibitor-related pneumonitis (CIP), affecting about...
2.
Zeng L, Zhang L, Li L, Liao X, Yin C, Zhang L, et al.
PeerJ
. 2024 Sep;
12:e18159.
PMID: 39346064
Recent breakthrough therapies have improved survival rates in non-small cell lung cancer (NSCLC), but a paradigm for prospective confirmation is still lacking. Patientdatasets were mainly downloaded from TCGA, CPTAC and...
3.
Yu Y, Li L, Luo B, Chen D, Yin C, Jian C, et al.
Biomed Pharmacother
. 2024 Mar;
174:116528.
PMID: 38555814
Lung cancer is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) constituting the majority, and its main subtype being lung adenocarcinoma (LUAD). Despite substantial advances...
4.
Zeng L, Chen X, Cui J, Zhang L, Li L, Yin C, et al.
J Thorac Dis
. 2024 Feb;
16(1):201-214.
PMID: 38410612
Background: Programmed cell death ligand 1 (PD-L1) blocking therapy has transformed the treatment of lung adenocarcinoma (LUAD), which has significantly changed the landscape of immunotherapy. We aimed to explore specific...
5.
Zeng L, Li L, Liao X, Zhang L, Yin C, Chen X, et al.
Med Oncol
. 2024 Jan;
41(2):42.
PMID: 38170412
In lung squamous cell carcinoma (LUSC), current cancer vaccines show promising effects, despite a lack of benefit for a large number of patients. We first identified the tumor antigens into...
6.
Yang Q, Li J, Zhang Z, Wu X, Liao T, Yu S, et al.
BMC Infect Dis
. 2021 Aug;
21(1):783.
PMID: 34372767
Background: The novel coronavirus disease 2019 (COVID-19) spreads rapidly among people and causes a pandemic. It is of great clinical significance to identify COVID-19 patients with high risk of death....
7.
Zhou Y, Yang Q, Ye J, Wu X, Hou X, Feng Y, et al.
BMC Infect Dis
. 2021 Aug;
21(1):760.
PMID: 34353293
Background: Coronavirus disease 2019 (COVID-19) has spread around the world. This retrospective study aims to analyze the clinical features of COVID-19 patients with cancer and identify death outcome related risk...
8.
Yang G, Feng D, Li F, Luo B, Zhu J, Yang Q, et al.
Radiother Oncol
. 2021 Aug;
163:76-82.
PMID: 34343545
Purpose: This randomized controlled phase II study investigated the efficacy, safety and underlying mechanism of maxillofacial and oral massage (MOM) in nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy. Methods: A...
9.
Zhao F, Xu H, Xue W, Li Y, Sun J, Wang F, et al.
J Biomater Appl
. 2020 Mar;
35(1):39-48.
PMID: 32192387
Currently, implantable fibrous medical devices still suffer from invisibility under current clinical imaging techniques. To address this problem, 2, 3, 5-triiodobenzoic acid (TIBA) was recruited as a contrast agent, and...
10.
Luo B, Wang Y, Lu H, Wu S, Lu Y, Shi S, et al.
Biomed Opt Express
. 2019 Oct;
10(10):5136-5148.
PMID: 31646036
Programmed death ligand-1 (PD-L1) plays an important role in tumor evasion from the host immune system. The level of soluble PD-L1 (sPD-L1) in serum is closely related to tumor aggressiveness...